Exosome-associated mitochondrial DNA from patients with myalgic encephalomyelitis/chronic fatigue syndrome stimulates human microglia to release IL-1β. — CFSMEATLAS
Exosome-associated mitochondrial DNA from patients with myalgic encephalomyelitis/chronic fatigue syndrome stimulates human microglia to release IL-1β.
Tsilioni, Irene, Natelson, Benjamin, Theoharides, Theoharis C · The European journal of neuroscience · 2022 · DOI
Quick Summary
This study found that after exercise, patients with ME/CFS have more pieces of DNA from their mitochondria (the energy-producing parts of cells) floating in their blood inside tiny particles called exosomes. When researchers tested these exosomes on immune cells in the lab, they triggered the release of IL-1β, a chemical that causes inflammation in the brain. This suggests that exercise might trigger a chain reaction involving these DNA-carrying particles that could contribute to ME/CFS symptoms.
Why It Matters
This study identifies a potential biological mechanism that could explain why ME/CFS patients experience symptom flares after physical activity—a hallmark feature called post-exertional malaise. Understanding this mechanism is crucial for developing targeted treatments that address the underlying cause rather than just managing symptoms. The findings also suggest that exosomal mtDNA and microglial activation could serve as measurable biomarkers to help diagnose and monitor ME/CFS.
Observed Findings
Mitochondrial DNA associated with serum exosomes is elevated in ME/CFS patients specifically after exercise, but not at rest.
Exosomes isolated from post-exercise ME/CFS serum stimulate significantly greater IL-1β release from cultured human microglia compared to control exosomes.
Baseline serum exosome mtDNA levels did not reliably distinguish ME/CFS patients from healthy controls, suggesting post-exercise state is important for detection.
The exosome-induced microglial response appears to be a direct effect on these brain immune cells rather than a general inflammatory response.
Inferred Conclusions
Post-exertional exosomal mtDNA release may represent a pathogenic factor in ME/CFS that triggers neuroinflammation through microglial activation.
Microglial activation via exosomal mtDNA could contribute to cognitive symptoms and post-exertional malaise observed in ME/CFS patients.
Exosomal mtDNA and microglial IL-1β production represent potential therapeutic targets for ME/CFS treatment.
Remaining Questions
Do elevated IL-1β levels in the brain correlate with the severity of ME/CFS symptoms, and do they persist after exercise or return to baseline?
What triggers the release of mtDNA-containing exosomes in response to exercise specifically in ME/CFS patients, and why don't healthy controls show the same response?
What This Study Does Not Prove
This study does not prove that exosomal mtDNA and IL-1β elevation directly cause ME/CFS symptoms in patients, only that this mechanism occurs in laboratory conditions. It also does not establish whether blocking IL-1β would improve ME/CFS symptoms or whether mtDNA elevation is the primary cause versus a consequence of other disease processes. Additionally, the study does not confirm that post-exertional mtDNA elevation occurs consistently across all ME/CFS patients or determine optimal exercise thresholds that trigger this response.
Would blocking IL-1β or inhibiting microglial activation improve symptoms in ME/CFS patients, and is this a viable therapeutic approach?
Are other inflammatory cytokines besides IL-1β involved in this exosome-mediated microglial activation, and what is the full cascade of immune responses triggered?